Dual Checkpoint Inhibition Boost from New Bifunctional Antibody

Researchers at Johns Hopkins University School of Medicine have developed a new class of bifunctional antibody-based immunotherapy that targets immune checkpoints, but simultaneously disables the production of immunosuppressive regulatory T cells (Tregs). The new molecules, dubbed Y-traps, comprise a Y-shaped antibody fused to a transforming growth factor beta (TGF-β) receptor domain that switches off the ability of TGF-β to trigger Tregs.Reporting in Nature Communications , the team d